To investigate the efficacy of telavancin in the treatment of bacteremia and infective endocarditis, the authors looked at data from the Telavancin Observational Use Registry, which reports on outcomes of patients treated with telavancin in clinical practice.
A total of 1,042 patients with infection were randomly assigned to receive either intravenous/oral DLX monotherapy or VAN (15mg/kg) with AZ for 5 to 14 days.
The study authors sought to contribute to the evidence base on gender differences in virologic and immunologic responses to ART in treatment-naïve individuals.
Participants included 464 hospitalized adults with cUTI or AP diagnosis, randomly assigned to be administered either ZTI-01 or piperacillin/tazobactam for a fixed 7 days.
Omadacycline is a novel, broad-spectrum aminomethylcycline related to tetracyclines; the OASIS phase 3 trial investigated whether it was non-inferior to linezolid.
Whereas epidemiological risk factors for CDI among adults are well known, data is limited for children.
Researchers assessed the risk of febrile seizures following inactivated influenza vaccine and pneumococcal conjugate vaccine-13 during 2013-14 and 2014-15 flu seasons.
Rates of viral failure were compared in HIV patients initiated on dolutegravir-based vs. other guideline recommended regimens in clinical care.
Two sequential administration groups were compared by demonstrating the antibody response curve and the reverse cumulative distribution curve analyses by serotype.
For adults aged ≥65 years, seasonal flu epidemics pose significant disease burden annually and not many vaccines are specifically formulated for this patient population.
Want to read more?
Please login or register first to view this content.